Orthofix Reports First Quarter 2021 Results

Orthofix Reports First Quarter 2021 Results




Orthofix Reports First Quarter 2021 Results

  • Net sales of $106 million, up 1% compared to prior year, after a strong recovery in March
  • U.S. Spinal Implants net sales grew 19% compared to prior year, as net sales increased for both Spine Fixation and Motion Preservation
  • Performed the first cervical and lumbar procedures utilizing our new 3D-printed titanium interbody implants with Nanovate™ Technology
  • Announced exclusive licensing agreement with Italy-based IGEA S.p.A. to expand our Bone Growth Therapies portfolio

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended March 31, 2021. Net sales were $105.6 million, earnings per share (“EPS”) was $(0.30) and adjusted EPS was $0.17.

“We are excited about the topline performance of the business during the first quarter, particularly as we continued to contend with the headwinds of the global pandemic and the added challenges of the recent severe winter weather-related disruption,” said Orthofix President and Chief Executive Officer Jon Serbousek. “We are pleased with the positive revenue impact from initiatives we put into place in 2020, including a focus on new product introductions and the development of our U.S. commercial channel. Both our M6-C™ artificial cervical disc and the FITBONE® lengthening nail delivered during the quarter, and we saw positive revenue contributions from increased product adoption driven by new strategic distribution partners.”

“Looking forward into 2021, we plan to continue to generate commercial momentum and execute future product launches to drive growth. An unrelenting focus on operational execution, product innovation and differentiation, and our commercial channel will continue to be core tenets of our growth strategy. We expect that products such as the M6-C artificial cervical disc, the FITBONE limb lengthening system, and our recently bolstered 3D-printed titanium spinal interbody portfolio to be important drivers of that growth.”

Financial Results Overview

The following table provides net sales by major product category by reporting segment:

 

 

Three Months Ended March 31,

 

(Unaudited, U.S. Dollars, in thousands)

 

2021

 

 

2020

 

 

Change

 

 

Constant

Currency

Change

 

Bone Growth Therapies

 

$

42,947

 

 

$

45,443

 

 

 

(5.5

%)

 

 

(5.5

%)

Spinal Implants

 

 

25,701

 

 

 

22,926

 

 

 

12.1

%

 

 

11.0

%

Biologics

 

 

13,692

 

 

 

13,949

 

 

 

(1.8

%)

 

 

(1.8

%)

Global Spine

 

 

82,340

 

 

 

82,318

 

 

 

0.0

%

 

 

(0.3

%)

Global Orthopedics 1

 

 

23,253

 

 

 

22,505

 

 

 

3.3

%

 

 

(2.5

%)

Net sales

 

$

105,593

 

 

$

104,823

 

 

 

0.7

%

 

 

(0.8

%)

1 Formerly referred to as Global Extremities

 

Gross profit decreased $1.7 million to $79.7 million. Gross margin decreased to 75.5% compared to 77.7% in the prior year period.

Net loss was $(5.8) million, or $(0.30) per share, compared to net income of $25.7 million, or $1.32 per share in the prior year period. Adjusted net income was $3.4 million, or $0.17 per share, compared to adjusted net income of $1.7 million, or $0.09 per share in the prior year period.

EBITDA was $1.8 million, compared to $12.4 million in the prior year period. Adjusted EBITDA was $14.0 million, or 13.3% of net sales, compared to $11.4 million, or 10.9% of net sales, in the prior year period.

Liquidity

As of March 31, 2021, cash, cash equivalents, and restricted cash totaled $95.1 million compared to $96.8 million as of December 31, 2020. As of March 31, 2021, the Company had no borrowings under its five year $300 million secured revolving credit facility. Cash flow from operations decreased $10.0 million to $2.4 million, while free cash flow decreased $9.9 million to $(2.3) million. Based primarily on the growth in M6-C artificial cervical disc sales volumes in the U.S., the company triggered a $15.0 million milestone payment during the first quarter in relation to its 2018 acquisition of Spinal Kinetics. The payment will be made during the second quarter of 2021.

IGEA S.p.A (“IGEA”) Exclusive License Agreement

Founded 40 years ago at the University of Modena, Italy, IGEA is a leader in the manufacturing and distribution of bone and joint cartilage stimulation systems and treats more than 20,000 patients every year. Orthofix entered into an exclusive license agreement to commercialize their innovative portfolio of bone, cartilage and soft tissue stimulation products in the U.S. and Canada. Under the terms of this agreement, Orthofix has the rights to pursue U.S. Food and Drug Administration approvals and commercialization of IGEA’s platform of orthopedic products, which are not currently available in the U.S. These products, which will be marketed under the Orthofix brand, will expand Orthofix’s bone growth therapies portfolio of Pulsed Electromagnetic Field (“PEMF”) products with additional treatment modalities and indications such as Low-intensity Pulsed Ultrasound (“LIPUS”) and Capacitive Coupling (“CC”) for fracture management. The license also includes new technologies designed to address joint inflammation, pain, and cartilage protection.

COVID-19 Impact

The global Coronavirus Disease 2019 (“COVID-19”) pandemic has significantly affected the Company’s customers, communities, employees and business operations. The pandemic has led to the cancellation or deferral of elective surgeries and procedures, restrictions on travel, the implementation of physical distancing measures, and the temporary or permanent closure of businesses. However, the Company remains focused on protecting the health and wellbeing of its employees, partners, patients, and the communities in which it operates while assuring the continuity of its business operations.

As of the date hereof, the Company expects the following net sales results for the year ended December 31, 2021, and for the quarter ended March 31, 2021, including the impact of any expected changes in foreign currency exchange rates:

 

 

Current 2021 Outlook

 

 

Previous 2021 Outlook

(Unaudited, U.S. Dollars, in millions, except per share data)

 

Low

 

 

High

 

 

Low

 

 

High

 

 

Net sales

 

$

455.0

 

1

$

465.0

 

1

$

445.0

 

 

$

460.0

 

 

Adjusted EBITDA

 

$

52.0

 

2

$

56.0

 

2

$

50.0

 

 

$

54.0

 

 

Adjusted EPS

 

$

0.52

 

3

$

0.62

 

3

$

0.45

 

 

$

0.55

 

 

1 Represents a year-over-year increase of 11.9% to 14.4% on a reported basis

2 Represents a year-over-year increase of 9.2% to 17.6%

3 Represents a year-over-year increase of 100.0% to 138.5%

The Company does not provide U.S. GAAP financial measures, other than net sales, on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, accounting fair value adjustments, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with U.S. GAAP.

Conference Call

Orthofix will host a conference call today at 8:30 AM Eastern time to discuss the Company’s financial results for the first quarter of 2021. Interested parties may access the conference call by dialing (833) 670-0709 in the U.S. and (343) 761-2533 outside the U.S., and referencing the conference ID 2675149. A replay of the call will be available for three weeks by dialing (800) 585-8367 in the U.S. and (416) 621-4642 outside the U.S., and entering the conference ID 2675149. A webcast of the conference call may be accessed at ir.Orthofix.com.

About Orthofix

Orthofix Medical Inc. is a global medical device and biologics company with a spine and orthopedics focus. The Company’s mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in over 70 countries via the Company’s sales representatives and distributors. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”). Factors that could cause or contribute to such differences may include, but are not limited to, (i) risks relating to the effects of the COVID-19 pandemic on our business, including (A) surgeries that use our products being delayed or cancelled as a result of hospitals and surgery centers being closed or limited to life-threatening and/or essential procedures, (B) portions of our global workforce being unable to work fully and/or effectively due to illness, quarantines, government actions (including “shelter in place” orders or advisories), facility closures or other reasons related to the pandemic, (C) disruptions to our supply chain, (D) customers and payors being unable to satisfy contractual obligations to us, including the ability to make timely payment for purchases, (E) general economic weakness in markets in which we operate affecting customer spending, and (F) other unpredictable aspects of the pandemic; (ii) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities; (iii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iv) development and acceptance of new products or product enhancements, (v) clinical and statistical verification of the benefits achieved via the use of our products, (vi) our ability to adequately manage inventory, (vii) our ability to recruit and retain management and key personnel, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). To the extent that the COVID-19 pandemic continues to adversely affect our business and financial results, it may also have the effect of heightening many of the other risks described in Part I, Item 1A under the heading Risk Factors in our 2020 Form 10-K, such as our ability to generate sufficient cash flows to run our business and our ability to protect our information technology networks and infrastructure from unauthorized access, misuse, malware, phishing and other events that could have a security impact as a result of our remote working environment or otherwise. As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.

This list of risks, uncertainties and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

 

ORTHOFIX MEDICAL INC.

Condensed Consolidated Statements of Operations

 

 

 

Three Months Ended

 

 

 

March 31,

 

(U.S. Dollars, in thousands, except share and per share data)

 

2021

 

 

2020

 

 

 

(unaudited)

 

Net sales

 

$

105,593

 

 

$

104,823

 

Cost of sales

 

 

25,914

 

 

 

23,409

 

Gross profit

 

 

79,679

 

 

 

81,414

 

Sales and marketing

 

 

50,785

 

 

 

54,313

 

General and administrative

 

 

16,444

 

 

 

17,865

 

Research and development

 

 

10,897

 

 

 

9,964

 

Acquisition-related amortization and remeasurement

 

 

4,469

 

 

 

(7,582

)

Operating income (loss)

 

 

(2,916

)

 

 

6,854

 

Interest expense, net

 

 

(417

)

 

 

(423

)

Other expense, net

 

 

(2,690

)

 

 

(798

)

Income (loss) before income taxes

 

 

(6,023

)

 

 

5,633

 

Income tax benefit

 

 

207

 

 

 

20,032

 

Net income (loss)

 

$

(5,816

)

 

$

25,665

 

 

 

 

 

 

 

 

 

 

Net income (loss) per common share:

 

 

 

 

 

 

 

 

Basic

 

$

(0.30

)

 

$

1.33

 

Diluted

 

 

(0.30

)

 

 

1.32

 

Weighted average number of common shares:

 

 

 

 

 

 

 

 

Basic

 

 

19,526,872

 

 

 

19,143,934

 

Diluted

 

 

19,526,872

 

 

 

19,299,820

 

 

ORTHOFIX MEDICAL INC.

Condensed Consolidated Balance Sheets

 

(U.S. Dollars, in thousands, except share data)

 

March 31,

2021

 

 

December 31,

2020

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

94,569

 

 

$

96,291

 

Restricted cash

 

 

488

 

 

 

530

 

Accounts receivable, net of allowances of $4,506 and $4,848, respectively

 

 

69,680

 

 

 

72,423

 

Inventories

 

 

84,180

 

 

 

84,635

 

Prepaid expenses and other current assets

 

 

14,434

 

 

 

16,500

 

Total current assets

 

 

263,351

 

 

 

270,379

 

Property, plant and equipment, net

 

 

62,467

 

 

 

63,613

 

Intangible assets, net

 

 

57,634

 

 

 

60,517

 

Goodwill

 

 

83,513

 

 

 

84,018

 

Deferred income taxes

 

 

26,140

 

 

 

25,042

 

Other long-term assets

 

 

20,769

 

 

 

22,292

 

Total assets

 

$

513,874

 

 

$

525,861

 

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

21,056

 

 

$

23,118

 

Current portion of finance lease liability

 

 

2,514

 

 

 

510

 

Other current liabilities

 

 

75,491

 

 

 

80,271

 

Total current liabilities

 

 

99,061

 

 

 

103,899

 

Long-term portion of finance lease liability

 

 

20,283

 

 

 

22,338

 

Other long-term liabilities

 

 

39,712

 

 

 

42,760

 

Total liabilities

 

 

159,056

 

 

 

168,997

 

Contingencies

 

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

 

 

 

Common shares $0.10 par value; 50,000,000 shares authorized;

19,474,384 and 19,423,874 issued and outstanding as of March 31,

2021 and December 31, 2020, respectively

 

 

1,947

 

 

 

1,942

 

Additional paid-in capital

 

 

297,629

 

 

 

292,291

 

Retained earnings

 

 

53,563

 

 

 

59,379

 

Accumulated other comprehensive income

 

 

1,679

 

 

 

3,252

 

Total shareholders’ equity

 

 

354,818

 

 

 

356,864

 

Total liabilities and shareholders’ equity

 

$

513,874

 

 

$

525,861

 

ORTHOFIX MEDICAL INC.

Non-GAAP Financial Measures

The following tables present reconciliations of operating income (loss), net income (loss), EPS, and net cash from operating activities, in each case calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to, as applicable, non-GAAP financial measures, referred to as “EBITDA,” “Adjusted EBITDA,” “Adjusted net income,” “Adjusted EPS,” and “Free cash flow” that exclude items specified in the tables. A more detailed explanation of the items excluded from these non-GAAP financial measures, as well as why management believes the non-GAAP financial measures are useful to them, is included following the reconciliations.

EBITDA and Adjusted EBITDA

 

 

Three Months Ended March 31, 2021

 

(Unaudited, U.S. Dollars, in thousands)

 

Global Spine

 

 

Global Orthopedics

 

 

Corporate

 

 

Total Orthofix

 

Operating income (loss)

 

$

8,112

 

 

$

(2,862

)

 

$

(8,166

)

 

$

(2,916

)

Other income (expense), net

 

 

(616

)

 

 

(1,438

)

 

 

(636

)

 

 

(2,690

)

Depreciation and amortization

 

 

2,615

 

 

 

1,620

 

 

 

973

 

 

 

5,208

 

Amortization of acquired intangibles

 

 

1,784

 

 

 

451

 

 

 

 

 

 

2,235

 

EBITDA

 

$

11,895

 

 

$

(2,229

)

 

$

(7,829

)

 

$

1,837

 

Share-based compensation

 

 

1,508

 

 

 

526

 

 

 

1,687

 

 

 

3,721

 

Foreign exchange impact

 

 

624

 

 

 

1,401

 

 

 

637

 

 

 

2,662

 

Strategic investments

 

 

 

 

 

1,100

 

 

 

311

 

 

 

1,411

 

Acquisition-related fair value adjustments

 

 

2,564

 

 

 

 

 

 

 

 

 

2,564

 

Legal judgments/settlements

 

 

(51

)

 

 

46

 

 

 

(54

)

 

 

(59

)

Succession and transition charges

 

 

30

 

 

 

 

 

 

 

 

 

30

 

Medical device regulation

 

 

503

 

 

 

507

 

 

 

814

 

 

 

1,824

 

Business interruption – COVID-19

 

 

2

 

 

 

6

 

 

 

13

 

 

 

21

 

Adjusted EBITDA

 

$

17,075

 

 

$

1,357

 

 

$

(4,421

)

 

$

14,011

 

 

 

 

Three Months Ended March 31, 2020

 

(Unaudited, U.S. Dollars, in thousands)

 

Global Spine

 

 

Global Orthopedics

 

 

Corporate

 

 

Total Orthofix

 

Operating income (loss)

 

$

18,559

 

 

$

(2,706

)

 

$

(8,999

)

 

$

6,854

 

Other income (expense), net

 

 

(25

)

 

 

(541

)

 

 

(232

)

 

 

(798

)

Depreciation and amortization

 

 

2,465

 

 

 

1,353

 

 

 

1,091

 

 

 

4,909

 

Amortization of acquired intangibles

 

 

1,418

 

 

 

 

 

 

 

 

 

1,418

 

EBITDA

 

$

22,417

 

 

$

(1,894

)

 

$

(8,140

)

 

$

12,383

 

Share-based compensation

 

 

1,524

 

 

 

626

 

 

 

1,609

 

 

 

3,759

 

Foreign exchange impact

 

 

51

 

 

 

509

 

 

 

13

 

 

 

573

 

Strategic investments

 

 

12

 

 

 

8

 

 

 

445

 

 

 

465

 

Acquisition-related fair value adjustments

 

 

(9,000

)

 

 

 

 

 

 

 

 

(9,000

)

(Gain) loss on investment securities

 

 

 

 

 

 

 

 

219

 

 

 

219

 

Legal judgments/settlements

 

 

(431

)

 

 

221

 

 

 

376

 

 

 

166

 

Succession and transition charges

 

 

133

 

 

 

1,099

 

 

 

434

 

 

 

1,666

 

Medical device regulation

 

 

205

 

 

 

149

 

 

 

299

 

 

 

653

 

Business interruption – COVID-19

 

 

333

 

 

 

179

 

 

 

11

 

 

 

523

 

Adjusted EBITDA

 

$

15,244

 

 

$

897

 

 

$

(4,734

)

 

$

11,407

 

 

Adjusted Net Income

 
 

 

 

Three Months Ended

March 31,

 

(Unaudited, U.S. Dollars, in thousands)

 

2021

 

 

2020

 

Net income (loss)

 

$

(5,816

)

 

$

25,665

 

Foreign exchange impact

 

 

2,662

 

 

 

573

 

Strategic investments

 

 

1,452

 

 

 

465

 

Acquisition-related fair value adjustments

 

 

2,564

 

 

 

(9,000

)

Amortization of acquired intangibles

 

 

2,239

 

 

 

1,418

 

Loss on investment securities

 

 

 

 

 

219

 

Legal judgments/settlements

 

 

(59

)

 

 

166

 

Succession and transition charges

 

 

30

 

 

 

1,666

 

Medical device regulation

 

 

1,824

 

 

 

653

 

Business interruption – COVID-19

 

 

23

 

 

 

523

 

Long-term income tax rate adjustment

 

 

(1,479

)

 

 

(20,657

)

Adjusted net income

 

$

3,440

 

 

$

1,691

 

 

Adjusted EPS

 
 

 

 

Three Months Ended

March 31,

 

(Unaudited, per diluted share)

 

2021

 

 

2020

 

EPS

 

$

(0.30

)

 

$

1.32

 

Foreign exchange impact

 

 

0.13

 

 

 

0.03

 

Strategic investments

 

 

0.07

 

 

 

0.03

 

Acquisition-related fair value adjustments

 

 

0.13

 

 

 

(0.46

)

Amortization of acquired intangibles

 

 

0.11

 

 

 

0.07

 

Loss on investment securities

 

 

 

 

 

0.01

 

Legal judgments/settlements

 

 

 

 

 

0.01

 

Succession and transition charges

 

 

 

 

 

0.09

 

Medical device regulation

 

 

0.09

 

 

 

0.03

 

Business interruption – COVID-19

 

 

 

 

 

0.03

 

Long-term income tax rate adjustment

 

 

(0.06

)

 

 

(1.07

)

Adjusted EPS

 

$

0.17

 

 

$

0.09

 

 

 

 

 

 

 

 

 

 

Weighted average number of diluted common shares (treasury stock method)

 

 

19,950,740

 

 

 

19,317,150

 

 

Free Cash Flow

 
 

 

 

Three Months Ended

March 31,

 

(Unaudited, U.S. Dollars, in thousands)

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

Net cash from operating activities

 

$

2,441

 

 

$

12,464

 

Capital expenditures

 

 

(4,781

)

 

 

(4,944

)

Free cash flow

 

$

(2,340

)

 

$

7,520

 

 

Constant Currency

Constant currency is a non-GAAP measure, which is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

EBITDA

EBITDA is a non-GAAP financial measure, which is calculated by adding interest income (expense), net; income tax expense (benefit); and depreciation and amortization to net income. EBITDA provides management with additional insight to its results of operations. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing our business.

Adjusted EBITDA, Adjusted Net Income and Adjusted EPS

These non-GAAP financial measures provide management with additional insight to its results of operations and are calculated using the following adjustments:

  • Share-based compensation – costs related to our share-based compensation plans, which include stock options, restricted stock, market-based restricted stock awards and our stock purchase plan; see the share-based compensation footnote in our Form 10-Q for the quarter ended March 31, 2021 for an allocation of these costs by consolidated statement of income line item; note that certain share-based compensation costs are instead included within succession and transition charges for 2020
  • Foreign exchange impact – gains and losses related to foreign currency transactions, which are recorded as other income (expense), net
  • Strategic investments – costs related to our strategic investments, such as due diligence and integration costs, which are primarily recorded as general and administrative expenses
  • Acquisition-related fair value adjustments – comprised of i) gains and losses related to remeasurement of contingent consideration to fair value, which are recorded as operating expenses, ii) the amortization of an adjustment made to inventory acquired to reflect the expected selling price of the acquired inventory less the cost of expected selling efforts and a reasonable profit allowance for the selling effort for finished goods inventory, which is recorded as cost of sales, and iii) costs recognized related to acquired in-process research and development assets, which were expensed immediately.
  • Amortization of acquired intangibles – amortization of intangible assets acquired in business combinations or asset acquisitions, including items such as developed technologies, customer relationships, trade names, manufacturing agreements, and other intangible assets, which are recorded in cost of sales or operating expenses
  • Loss on investment securities – net gains or losses recognized (realized or unrealized) within other income (expense), net relating to certain of our investments
  • Legal judgments/settlements – adverse or favorable legal judgments or negotiated legal settlements, which are recorded as general and administrative expenses
  • Succession and transition charges – costs related to the transition of certain named executive officers and certain targeted restructuring costs, including any cessation and onboarding amounts, accelerated share-based compensation expense, consulting services, and other related expenses, which are primarily recorded as general and administrative expenses
  • Medical device regulation – incremental costs incurred (i) to establish initial compliance with the regulations set forth by the European Union Medical Device Regulation (“MDR”) and the U.S. Food and Drug Administration related to our currently-approved medical devices, which are recorded primarily as research and development expenses, and (ii) related to rationalization of certain product lines that we do not expect to continue to market subsequent to the effective date of these regulations, which are recorded primarily as costs of sales
  • Business interruption – COVID-19 – gains and losses related to the realized effects the COVID-19 pandemic has had on our business o

Contacts

Orthofix Medical Inc.

Alexa Huerta

P: 214-937-3190

E: alexahuerta@orthofix.com

Read full story here